4D Molecular Therapeutics Inc. Financials
Financial Health Signals
Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores
4D Molecular Therapeutics Inc. has an operating margin of -507678.4%, meaning the company retains $-507678 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is down from -544.7% the prior year.
4D Molecular Therapeutics Inc.'s revenue declined 99.8% year-over-year, from $20.7M to $37K. This contraction results in a growth score of 0/100.
4D Molecular Therapeutics Inc. carries a low D/E ratio of 0.10, meaning only $0.10 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 14.92, 4D Molecular Therapeutics Inc. holds $14.92 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.
While 4D Molecular Therapeutics Inc. generated -$134.6M in operating cash flow, capex of $3.8M consumed most of it, leaving -$138.4M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.
4D Molecular Therapeutics Inc. passes 2 of 9 financial strength tests. 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.
For every $1 of reported earnings, 4D Molecular Therapeutics Inc. generates $0.84 in operating cash flow (-$134.6M OCF vs -$160.9M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
This page shows 4D Molecular Therapeutics Inc. (FDMT) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Key Financial Metrics
4D Molecular Therapeutics Inc. generated $37K in revenue in fiscal year 2024. This represents a decrease of 99.8% from the prior year.
4D Molecular Therapeutics Inc.'s EBITDA was -$183.2M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 68.6% from the prior year.
4D Molecular Therapeutics Inc. generated -$138.4M in free cash flow in fiscal year 2024, representing cash available after capex. This represents a decrease of 76.1% from the prior year.
4D Molecular Therapeutics Inc. reported -$160.9M in net income in fiscal year 2024. This represents a decrease of 59.5% from the prior year.
4D Molecular Therapeutics Inc. earned $-2.98 per diluted share (EPS) in fiscal year 2024. This represents a decrease of 15.5% from the prior year.
4D Molecular Therapeutics Inc. held $149.3M in cash against $0 in long-term debt as of fiscal year 2024.
4D Molecular Therapeutics Inc. had 46M shares outstanding in fiscal year 2024. This represents an increase of 6.3% from the prior year.
4D Molecular Therapeutics Inc.'s operating margin was -507678.4% in fiscal year 2024, reflecting core business profitability. This is down 507133.7 percentage points from the prior year.
4D Molecular Therapeutics Inc.'s net profit margin was -434778.4% in fiscal year 2024, showing the share of revenue converted to profit. This is down 434291.8 percentage points from the prior year.
4D Molecular Therapeutics Inc. invested $141.3M in research and development in fiscal year 2024. This represents an increase of 45.5% from the prior year.
4D Molecular Therapeutics Inc. invested $3.8M in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents an increase of 36.6% from the prior year.
FDMT Income Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $90K+500.0% | $15K+7.1% | $14K+1300.0% | $1K-80.0% | $5K-82.1% | $28K+255.6% | -$18K-100.1% | $20.2M |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $49.4M+3.1% | $48.0M+17.8% | $40.7M-5.5% | $43.1M+35.2% | $31.9M+14.3% | $27.9M+7.1% | $26.0M+3.9% | $25.1M |
| SG&A Expenses | $11.8M+2.8% | $11.5M-10.9% | $12.9M-0.7% | $13.0M+22.9% | $10.6M+3.0% | $10.3M-2.9% | $10.6M+16.3% | $9.1M |
| Operating Income | -$61.2M-2.9% | -$59.5M-10.9% | -$53.6M+4.4% | -$56.1M-32.2% | -$42.5M-11.3% | -$38.1M-4.1% | -$36.7M-162.3% | -$14.0M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | N/A | $0 |
| Net Income | -$56.9M-4.1% | -$54.7M-13.9% | -$48.0M+3.4% | -$49.7M-42.1% | -$35.0M-7.9% | -$32.4M-0.4% | -$32.3M-214.8% | -$10.3M |
| EPS (Diluted) | $-1.01-3.1% | $-0.98-14.0% | $-0.86+4.4% | $-0.90-42.9% | $-0.63+4.5% | $-0.66+4.3% | $-0.69-187.5% | $-0.24 |
FDMT Balance Sheet
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $424.0M-10.5% | $473.6M-8.2% | $515.7M-8.0% | $560.4M-9.6% | $620.1M-1.6% | $629.9M+85.3% | $339.9M-6.0% | $361.6M |
| Current Assets | $312.4M+3.0% | $303.3M-8.8% | $332.6M-23.5% | $434.9M-21.3% | $552.6M+3.2% | $535.6M+80.6% | $296.6M-9.6% | $328.2M |
| Cash & Equivalents | $48.6M-37.1% | $77.2M-42.2% | $133.5M-10.6% | $149.3M-21.0% | $189.1M-31.4% | $275.6M+10.6% | $249.1M-9.6% | $275.7M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $55.0M+4.3% | $52.7M+14.7% | $46.0M-7.6% | $49.8M+56.6% | $31.8M+8.4% | $29.3M-8.5% | $32.1M+1.2% | $31.7M |
| Current Liabilities | $37.1M+7.0% | $34.7M+28.9% | $26.9M-7.7% | $29.1M+50.2% | $19.4M+18.3% | $16.4M-13.4% | $19.0M+4.3% | $18.2M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $369.0M-12.3% | $420.9M-10.4% | $469.7M-8.0% | $510.6M-13.2% | $588.3M-2.0% | $600.6M+95.1% | $307.8M-6.7% | $329.9M |
| Retained Earnings | -$735.7M-8.4% | -$678.8M-8.8% | -$624.2M-8.3% | -$576.2M-19.4% | -$482.7M-7.8% | -$447.7M-7.8% | -$415.3M-8.4% | -$383.0M |
FDMT Cash Flow Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$46.5M-7.2% | -$43.4M+9.2% | -$47.8M-4.1% | -$45.9M-51.6% | -$30.2M-4.0% | -$29.1M-18.0% | -$24.6M-2005.0% | -$1.2M |
| Capital Expenditures | -$91K-237.9% | $66K-89.5% | $631K-33.5% | $949K+171.9% | $349K-50.8% | $710K+29.3% | $549K+35.6% | $405K |
| Free Cash Flow | -$46.6M-7.2% | -$43.4M+10.2% | -$48.4M-3.4% | -$46.8M-53.0% | -$30.6M-2.7% | -$29.8M-18.3% | -$25.2M-1498.9% | -$1.6M |
| Investing Cash Flow | $17.8M+228.3% | -$13.9M-143.4% | $31.9M+352.6% | $7.1M+109.6% | -$73.5M+72.1% | -$263.3M-3839.8% | -$6.7M-122.3% | $30.0M |
| Financing Cash Flow | $116K | N/A | N/A | $601K-96.5% | $17.2M-94.6% | $318.8M+6595.3% | $4.8M-54.9% | $10.6M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
FDMT Financial Ratios
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | -67983.3%+328390.0pp | -396373.3%-13366.2pp | -383007.1%+5228692.9pp | -5611700.0%-4762580.0pp | -849120.0%-712920.0pp | -136200.0% | N/A | -69.2% |
| Net Margin | -63195.6%+301191.1pp | -364386.7%-21729.5pp | -342657.1%+4624442.9pp | -4967100.0%-4268040.0pp | -699060.0%-583342.1pp | -115717.9% | N/A | -50.8% |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -13.4%-1.9pp | -11.5%-2.2pp | -9.3%-0.4pp | -8.9%-3.2pp | -5.6%-0.5pp | -5.1%+4.4pp | -9.5%-6.7pp | -2.8% |
| Current Ratio | 8.42-0.3 | 8.75-3.6 | 12.36-2.6 | 14.92-13.6 | 28.48-4.2 | 32.65+17.0 | 15.65-2.4 | 18.07 |
| Debt-to-Equity | 0.15+0.0 | 0.13+0.0 | 0.100.0 | 0.10+0.0 | 0.050.0 | 0.05-0.1 | 0.100.0 | 0.10 |
| FCF Margin | -51765.6%+237854.4pp | -289620.0%+56015.7pp | -345635.7%+4335564.3pp | -4681200.0%-4069360.0pp | -611840.0%-505418.6pp | -106421.4% | N/A | -7.8% |
Similar Companies
Frequently Asked Questions
What is 4D Molecular Therapeutics Inc.'s annual revenue?
4D Molecular Therapeutics Inc. (FDMT) reported $37K in total revenue for fiscal year 2024. This represents a -99.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is 4D Molecular Therapeutics Inc.'s revenue growing?
4D Molecular Therapeutics Inc. (FDMT) revenue declined by 99.8% year-over-year, from $20.7M to $37K in fiscal year 2024.
Is 4D Molecular Therapeutics Inc. profitable?
No, 4D Molecular Therapeutics Inc. (FDMT) reported a net income of -$160.9M in fiscal year 2024, with a net profit margin of -434778.4%.
What is 4D Molecular Therapeutics Inc.'s earnings per share (EPS)?
4D Molecular Therapeutics Inc. (FDMT) reported diluted earnings per share of $-2.98 for fiscal year 2024. This represents a -15.5% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is 4D Molecular Therapeutics Inc.'s EBITDA?
4D Molecular Therapeutics Inc. (FDMT) had EBITDA of -$183.2M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is 4D Molecular Therapeutics Inc.'s operating margin?
4D Molecular Therapeutics Inc. (FDMT) had an operating margin of -507678.4% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.
What is 4D Molecular Therapeutics Inc.'s net profit margin?
4D Molecular Therapeutics Inc. (FDMT) had a net profit margin of -434778.4% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is 4D Molecular Therapeutics Inc.'s free cash flow?
4D Molecular Therapeutics Inc. (FDMT) generated -$138.4M in free cash flow during fiscal year 2024. This represents a -76.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is 4D Molecular Therapeutics Inc.'s operating cash flow?
4D Molecular Therapeutics Inc. (FDMT) generated -$134.6M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are 4D Molecular Therapeutics Inc.'s total assets?
4D Molecular Therapeutics Inc. (FDMT) had $560.4M in total assets as of fiscal year 2024, including both current and long-term assets.
What are 4D Molecular Therapeutics Inc.'s capital expenditures?
4D Molecular Therapeutics Inc. (FDMT) invested $3.8M in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does 4D Molecular Therapeutics Inc. spend on research and development?
4D Molecular Therapeutics Inc. (FDMT) invested $141.3M in research and development during fiscal year 2024.
How many shares does 4D Molecular Therapeutics Inc. have outstanding?
4D Molecular Therapeutics Inc. (FDMT) had 46M shares outstanding as of fiscal year 2024.
What is 4D Molecular Therapeutics Inc.'s current ratio?
4D Molecular Therapeutics Inc. (FDMT) had a current ratio of 14.92 as of fiscal year 2024, which is generally considered healthy.
What is 4D Molecular Therapeutics Inc.'s debt-to-equity ratio?
4D Molecular Therapeutics Inc. (FDMT) had a debt-to-equity ratio of 0.10 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is 4D Molecular Therapeutics Inc.'s return on assets (ROA)?
4D Molecular Therapeutics Inc. (FDMT) had a return on assets of -28.7% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is 4D Molecular Therapeutics Inc.'s cash runway?
Based on fiscal year 2024 data, 4D Molecular Therapeutics Inc. (FDMT) had $149.3M in cash against an annual operating cash burn of $134.6M. This gives an estimated cash runway of approximately 13 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is 4D Molecular Therapeutics Inc.'s Piotroski F-Score?
4D Molecular Therapeutics Inc. (FDMT) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are 4D Molecular Therapeutics Inc.'s earnings high quality?
4D Molecular Therapeutics Inc. (FDMT) has an earnings quality ratio of 0.84x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is 4D Molecular Therapeutics Inc.?
4D Molecular Therapeutics Inc. (FDMT) scores 40 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.